ARA-290 vs Diclofenac Topical
A side-by-side research comparison of ARA-290 and Diclofenac Topical across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | ARA-290 | Diclofenac Topical |
|---|---|---|
| Full name | Cibinetide (ARA-290) | Diclofenac Sodium Topical Gel (Voltaren) |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Investigational | FDA Approved (OTC) |
| Mechanism | Selectively activates the innate repair receptor (a heteromer of the EPO receptor and the beta-common receptor), triggering anti-inflammatory and tissue-protective signaling while avoiding hematopoietic stimulation. | Inhibits cyclooxygenase-1 and -2 (COX-1/2) locally in tissue, reducing prostaglandin E2 synthesis at the inflammation site. Topical delivery achieves therapeutic tissue concentrations with plasma levels <5% of oral dosing. |
| Molecular weight | ~1257 Da | 318.13 Da (sodium salt) |
| Half-life | Short (minutes in plasma); effects outlast plasma levels | ~1-2 hours (plasma); tissue penetration lasts 12+ hours |
| Bioavailability | High via subcutaneous injection | ~6% systemic (topical); local tissue levels therapeutic |
| Typical dose | 1-4 mg per dose | 4g gel (1% or 2%) per joint |
| Frequency | Daily during a course | 3-4x daily |
| Route | Subcutaneous injection | Topical gel |
ARA-290 reported benefits
- Reduces neuropathic pain
- Anti-inflammatory tissue protection
- Supports small-fiber nerve repair
- No increase in red blood cell mass (unlike EPO)
Diclofenac Topical reported benefits
- Localized pain relief
- Minimal systemic side effects
- Joint and tendon inflammation
- Post-workout recovery
- No GI ulcer risk
- OTC availability
Related comparisons
Research and educational reference only. Not medical advice.